Skip to navigation Skip to content

Clinical Trial: Fenebrutinib

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 734
Medication: Fenebrutinib, a highly selective, orally administered inhibitor of BTK
Location: Colorado
Institutions: Advanced Neurology of CO/Advanced Neurosciences Research
2121 East Harmony Road Suite 180 Fort Collins CO 80528
  Contact Information
Jennifer Gentilcore
970-237-2979
advneurosciences@gmail.com

Funding:

F. Hoffmann-La Roche Ltd

Description

A study to evaluate the effectiveness and safety of fenebrutinib on disability progression and relapse rate. Eligible participants will be randomly assigned to receive either fenebrutinib or teriflunomide. Some may then  receive fenebrutinib during an open label extension.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.